The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

propiverin     (1-methyl-4-piperidyl) 2,2-diphenyl-2...

Synonyms: Propiverine, Propiverino, Propiverinum, SureCN94695, CHEMBL1078261, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Propiverine


High impact information on Propiverine


Chemical compound and disease context of Propiverine


Biological context of Propiverine


Anatomical context of Propiverine


Associations of Propiverine with other chemical compounds


Gene context of Propiverine

  • Propiverine had no relevant effect on CYP2C9, CYP2C19, and CYP1A2 (90% CI for test/reference ratios 0.93-1.00, 0.84-0.96, and 0.97-1.07, respectively) [8].
  • Results show that Propiverine induced several monooxygenases and CYP2B expression dose dependently [20].
  • Furthermore, the inhibitory potency of propiverine on P450 enzymes was evaluated in competition assays with three most specific monooxygenases [20].
  • Influence of propiverine on hepatic microsomal cytochrome p450 enzymes in male rats [20].
  • In man propiverine is bound to serum albumin at a single site with high affinity (KA1 = 1.45 x 10(4) L mol-1) and at least two sites with low affinity (KA2 = 2.5 x 10(2) L mol-1) [21].

Analytical, diagnostic and therapeutic context of Propiverine


  1. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. Lee, K.S., Choo, M.S., Kim, D.Y., Kim, J.C., Kim, H.J., Min, K.S., Lee, J.B., Jeong, H.J., Lee, T., Park, W.H. J. Urol. (2005) [Pubmed]
  2. Efficacy and cardiac safety of propiverine in elderly patients - a double-blind, placebo-controlled clinical study. Dorschner, W., Stolzenburg, J.U., Griebenow, R., Halaska, M., Schubert, G., Mürtz, G., Frank, M., Wieners, F. Eur. Urol. (2000) [Pubmed]
  3. Propiverine-induced Parkinsonism: a case report and a pharmacokinetic/pharmacodynamic study in mice. Matsuo, H., Matsui, A., Nasu, R., Takanaga, H., Inoue, N., Hattori, F., Ohtani, H., Sawada, Y. Pharm. Res. (2000) [Pubmed]
  4. Pharmacokinetics and safety of propiverine in patients with fatty liver disease. Siepmann, M., Nokhodian, A., Thümmler, D., Kirch, W. Eur. J. Clin. Pharmacol. (1998) [Pubmed]
  5. Pharmacodynamics of propiverine and three of its main metabolites on detrusor contraction. Wuest, M., Hecht, J., Christ, T., Braeter, M., Schoeberl, C., Hakenberg, O.W., Wirth, M.P., Ravens, U. Br. J. Pharmacol. (2005) [Pubmed]
  6. Activation of the rostral pontine reticular formation increases the spinal glycine level and inhibits bladder contraction in rats. Nishijima, S., Sugaya, K., Miyazato, M., Shimabukuro, S., Morozumi, M., Ogawa, Y. J. Urol. (2005) [Pubmed]
  7. Propiverine and metabolites: differences in binding to muscarinic receptors and in functional models of detrusor contraction. Wuest, M., Weiss, A., Waelbroeck, M., Braeter, M., Kelly, L.U., Hakenberg, O.W., Ravens, U. Naunyn Schmiedebergs Arch. Pharmacol. (2006) [Pubmed]
  8. Effect of propiverine on cytochrome P450 enzymes: a cocktail interaction study in healthy volunteers. Tomalik-Scharte, D., Jetter, A., Kinzig-Schippers, M., Skott, A., Sörgel, F., Klaassen, T., Kasel, D., Harlfinger, S., Doroshyenko, O., Frank, D., Kirchheiner, J., Bräter, M., Richter, K., Gramatté, T., Fuhr, U. Drug Metab. Dispos. (2005) [Pubmed]
  9. Treatment of the overactive bladder syndrome with muscarinic receptor antagonists - a matter of metabolites? Michel, M.C., Hegde, S.S. Naunyn Schmiedebergs Arch. Pharmacol. (2006) [Pubmed]
  10. Quantification of propiverine by liquid chromatography/electrospray tandem mass spectrometry: application to a bioequivalence study of two formulations in healthy subjects. Cho, S.H., Lee, H.W., Im, H.T., Park, W.S., Baek, M., Lee, K.T. Journal of pharmaceutical and biomedical analysis. (2005) [Pubmed]
  11. Clinical and urodynamic effects of propiverine in patients suffering from urgency and urge incontinence. A multicentre dose-optimizing study. Mazur, D., Wehnert, J., Dorschner, W., Schubert, G., Herfurth, G., Alken, R.G. Scandinavian journal of urology and nephrology. (1995) [Pubmed]
  12. Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome. Abrams, P., Cardozo, L., Chapple, C., Serdarevic, D., Hargreaves, K., Khullar, V. International journal of urology : official journal of the Japanese Urological Association. (2006) [Pubmed]
  13. Effects of antimuscarinic drugs on both urinary frequency and cognitive impairment in conscious, nonrestrained rats. Oka, T., Nakano, K., Kirimoto, T., Matsuura, N. Jpn. J. Pharmacol. (2001) [Pubmed]
  14. Muscarinic receptor binding characteristics in rat tissues after oral administration of oxybutynin and propiverine. Oki, T., Yamada, S., Tohma, A., Kimura, R. Biol. Pharm. Bull. (2001) [Pubmed]
  15. Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia--a double-blind, placebo-controlled clinical trial. Stöhrer, M., Madersbacher, H., Richter, R., Wehnert, J., Dreikorn, K. Spinal Cord (1999) [Pubmed]
  16. Inhibitory effects of propiverine on rat and guinea-pig urinary bladder muscle. Tokuno, H., Chowdhury, J.U., Tomita, T. Naunyn Schmiedebergs Arch. Pharmacol. (1993) [Pubmed]
  17. Propiverine versus tolterodine: efficacy and tolerability in patients with overactive bladder. Jünemann, K.P., Halaska, M., Rittstein, T., Mürtz, G., Schnabel, F., Brünjes, R., Nurkiewicz, W. Eur. Urol. (2005) [Pubmed]
  18. Comparison of the in vitro skin penetration of propiverine with that of terodiline. Ogiso, T., Iwaki, M., Hirota, T., Tanino, T., Muraoka, O. Biol. Pharm. Bull. (1995) [Pubmed]
  19. Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents. Ohtake, A., Saitoh, C., Yuyama, H., Ukai, M., Okutsu, H., Noguchi, Y., Hatanaka, T., Suzuki, M., Sato, S., Sasamata, M., Miyata, K. Biol. Pharm. Bull. (2007) [Pubmed]
  20. Influence of propiverine on hepatic microsomal cytochrome p450 enzymes in male rats. Walter, R., Ullmann, C., Thummler, D., Siegmund, W. Drug Metab. Dispos. (2003) [Pubmed]
  21. In-vitro binding of propiverine hydrochloride and some of its metabolites to serum albumin in man. Meisel, P., Langner, S., Siegmund, W. J. Pharm. Pharmacol. (1997) [Pubmed]
  22. A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. Madersbacher, H., Halaska, M., Voigt, R., Alloussi, S., Höfner, K. BJU international. (1999) [Pubmed]
  23. Kinetics of propiverine as assessed by radioreceptor assay in poor and extensive metabolizers of debrisoquine. Müller, C., Siegmund, W., Huupponen, R., Kaila, T., Franke, G., Iisalo, E., Zschiesche, M. European journal of drug metabolism and pharmacokinetics. (1993) [Pubmed]
  24. Effects of Byakko-ka-ninjin-to on salivary secretion and bladder function in rats. Sakaguchi, M., Goto, K., Ichiki, H., Hattori, N., Iizuka, A., Yamamoto, M., Takeda, S., Ishige, A., Aburada, M., Yasuda, M., Yamamoto, T. Journal of ethnopharmacology. (2005) [Pubmed]
WikiGenes - Universities